SEC Tracker
Get the app

Zymeworks ZYME

Zymeworks FY 2024: revenue $76.3M, flat; diluted EPS −$1.62

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Zymeworks reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$76.3MFlat against $76.0M in FY 202310-K income statement, on EDGAR
  2. Net income−$122.7MAgainst −$118.7M in FY 202310-K income statement, on EDGAR
  3. Diluted EPS−$1.62Against −$1.72 in FY 202310-K income statement, on EDGAR
  4. Cash and cash equivalents$66.1M−58% from $157.6M in FY 202310-K balance sheet, on EDGAR
  5. Cash from operations−$110.0MAgainst −$118.3M in FY 202310-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Zymeworks files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Anaptysbio ANAB public float $633M, Dec 31, 2025
  2. Amphastar Pharmaceuticals AMPH public float $633M, Jun 30, 2025
  3. ImmunityBio IBRX public float $690M, Jun 30, 2025
  4. Evoke Pharma EVOK
  5. Anavex Life Sciences AVXL public float $708M, Mar 31, 2025, over 18 months old

Data on this page was fetched . The filing on SEC.gov is the record.